Oral PCSK9 Inhibitor Enlicitide Slashes LDL Cholesterol by Over 56 Percent in Pooled Trial Analysis
A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by more than ...
A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by more than ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine